Filed in 2009, the patent will cover inecalcitol doses higher than one milligram (mg) per day until 2029.
Currently-marketed vitamin D analogues for indications such as rickets, osteoporosis or chronic kidney disease, do not exceed 10 microgram per day.
The maximal tolerated dose of inecalcitol has been determined to be 4 mg per day in hormone-refractory prostate cancer patients.
As the ability to treat patients with a vitamin D analogue in the milligram dose range is totally new, inecalcitol is suited to reach efficacious levels without side effects in new indications such as cancer or psoriasis by oral administration.
The same patent application is still under evaluation by the US Patent and Trademark Office and by the World Intellectual Property Organization under the Patent Cooperation Treaty (PCT) procedure.
Hybrigenics CEO Remi Delansorne said the patent stems from proprietary findings generated by Hybrigenics and will be further strengthening the existing intellectual property position of inecalcitol for 20 years